Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0759 ET – Shares in European pharmaceutical companies are mostly ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 ...

To layoff 5,000 employees by the end of the year; aims to reduce operating expenses by approximately $1.5 billion by 2027.

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...